drugset / Trial / NCT06319235

Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG®

NCT06319235 ↗

Phase 1/2 Unknown 52 enrolled MB PHARMA s.r.o.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

DUOFAG® is a phage cocktail containing bacteriophages active against Staphylococcus aureus and Pseudomonas aeruginosa. It is an investigational medicinal product for the treatment of surgical site infections caused by S. aureus and P. aeruginosa. The primary objective of the study is to demonstrate the safety of DUOFAG® and the clinical and microbiological change within 10 weeks after the start of treatment or until healing.

Timeline

Start
2023-10-27
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DUOFAG® Other / unclassified 1e+07 unknown Topical